Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study ☆ ☆ Supported by National Cancer Institute Cancer Center Core Grant CA 16672. Presented in part at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, May 20, 2000. There is no financial relationship between any of the authors and any person, place, or thing that is included in this report.
Titel:
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study ☆ ☆ Supported by National Cancer Institute Cancer Center Core Grant CA 16672. Presented in part at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, May 20, 2000. There is no financial relationship between any of the authors and any person, place, or thing that is included in this report.
Auteur:
Kim, Jeri Millikan, Randall E. Smith, Terry L. Tu, Shi-Ming Pagliaro, Lance C. Logothetis, Christopher J.